Clinical Trials Logo

Clinical Trial Summary

Usage of osmotic agents is a standard practice in neuroanesthesia since cerebral edema is a very common situation for patients with pathology in the brain. Cerebral edema is defined as the accumulation of fluid in the intracellular or extracellular compartments of the brain. Among other situations that have nothing to do with the brain, a supratentorial pathology such as a tumor, traumatic injury or an aneurysm, will lead to disruption of blood-brain barrier, and energy crisis of the cells that will cause mainly vasogenic and cytotoxic cerebral edema. The most common monitoring method for "measuring" cerebral edema is ICP (intracranial pressure) in which normal values are (with differences in the bibliography) 10-15 mmHg. The osmotic agents used most in neuroanesthesia are mannitol 20% and hypertonic NaCl 7.5% or 3%. Their brain relaxation effectiveness is supposed to be quite the same between the two different agents. Their main difference is that mannitol induces diuresis. Also, electrolyte disorders are another possibility after mannitol infusion. On the other hand, NaCl 7.5% causes vasodilation, does not induce diuresis and hemodynamically, even though it reduces SBP, it raises CO because of its excessive vasodilation. But both reduce cerebral edema due to the change of osmotic pressure in the vessels, that leads to extracting water from brain cells. A supratentorial craniotomy is de facto worsening the oxygenation and metabolism condition of the surgical site, adding to the problem the intracranial pathology causes in the first place. So if oxygen provided is low and the metabolic rate is high, the rate of anaerobic metabolism will raise. Measuring the oxygen in the jugular bulb is the most reliable monitoring method of cerebral oxygenation and metabolism. It becomes evident that optimization of cerebral oxygenation during a craniotomy will possibly affect the outcome of a patient, by improving it. So, if any superiority of one osmotic agent over the other could be demonstrated this will be very helpful in the decision making in routine clinical practice.


Clinical Trial Description

Each participant will receive standard monitoring (ECG, SpO2, SBP, BIS, urine output, temperature). More detailed hemodynamic monitoring will be obtained by Edwards Lifesciences ClearSight system (CO, CI, SV, SVI, SVV, SVR, SVRI). TCI Propofol and Remifentanil will be the agents of choice for induction and maintenance in anesthesia and cisatracurium will be used for neuromuscular blockade for intubation. Protective mechanical ventilation will be chosen (7ml/kg IBW) with a Respiratory rate to obtain a PaCO2 of 35-40 mmHg. PEEP will be changed for the best PaO2/FiO2 ratio and FiO2 of choice will be 0.5. The radial artery catheterization will be applied for direct blood pressure measurement and arterial blood gas sampling ( pH, PaO2, PaCO2, HCO3, BE, Osmolality, Lactic acid, Hb, Glucose, Na, K will be measured). The jugular bulb ipsilateral to the craniotomy site will be catheterized for receiving blood samples for blood gas analysis. The following oxygenation and metabolic parameters / derivates will be measured or calculated: SjvO2, pH, PjvO2, PjvCO2, HCO3, BE, Osmolality, Lactic acid jv, Hb, Glucose, Na, K, AjvDO2, AjvCO2, O2ERbr, eRQbr, AjvDL, and LOI. The osmotic agent will be administered 20 minutes before dura matter incision. Before the dura mater opening the subdural space pressure will be measured and relevant CPP will be calculated. Brain Relaxation Score will be assessed by the neurosurgeon. Phases - T0: 5 minutes before administration of the osmotic agent - T15: 15 minutes after administration of the osmotic agent - T30: 30 minutes after administration of the osmotic agent - T60: 60 minutes after administration of the osmotic agent - T90: 90 minutes after administration of the osmotic agent - T120: 120 minutes after administration of the osmotic agent - T180: 180 minutes after administration of the osmotic agent - T240: 240 minutes after administration of the osmotic agent Blood samples for measuring S-100b will be collected at phases T0, T240 and 12 hours after osmotic agent administration. Postoperative complications, length of ICU stay, GOS-E (Glasgow Outcome Scale) and other neurological deficits will be recorded. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03573999
Study type Interventional
Source Aristotle University Of Thessaloniki
Contact
Status Completed
Phase Phase 4
Start date June 29, 2018
Completion date December 20, 2019

See also
  Status Clinical Trial Phase
Recruiting NCT04528004 - Mechanistic Studies of Nicotinamide Riboside in Human Heart Failure Early Phase 1
Completed NCT04597983 - Effect of 8-week Intake of 2S-hesperidin on Performance, Body Composition and Biochemicals Markers in Amateur Cyclists N/A
Completed NCT03445234 - Blueberries, Bananas, Exercise Recovery N/A
Recruiting NCT04892199 - Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication? Phase 4
Active, not recruiting NCT05070585 - Isothiocyanates and Metabolic Health Phase 1/Phase 2
Not yet recruiting NCT05494151 - Metabolic Substrate of Patients With Myocardial Infarction With and Without Modifiable Cardiovascular Risk Factors
Completed NCT04787952 - Insight Into New Brown Adipose Tissue Activators.
Completed NCT05758857 - Multiple Risk Factor Intervention Trial N/A
Completed NCT02689882 - "Pharmacokinetic Study of Nicotinamide Riboside" Phase 1
Completed NCT01674426 - Pathogenesis of Functional Hypothalamic Amenorrhea N/A
Recruiting NCT06252922 - Diet-Induced Changes in GEnetic Material
Completed NCT06326840 - Clinical Efficacy and Adverse Reactions of Antipsychotic Treatment N/A
Recruiting NCT06345937 - Multiple Risk Factor Intervention Trial (Ms. FIT) N/A
Recruiting NCT06392360 - Betaine, Exercise Performance, and Gut Permeability N/A
Completed NCT04009642 - Cardiac Rest and Stress Metabolism in Patients With Type 2 Diabetes
Withdrawn NCT03515642 - Exercise, Gut Microbiota in Sedentary Adults With Overweight N/A
Recruiting NCT06333184 - Smoothies and Blood Sugars N/A
Not yet recruiting NCT05773183 - Exploring the Relationship Between Androgen Metabolism, Metabolic Disease and Skeletal Muscle Energy Balance in Men
Completed NCT04266665 - Effect of Dexmedetomidine on Brain Homeostasis and Neurocognitive Outcome Phase 4
Completed NCT03697928 - Markers of Carnitine Acetyltransferase (CrAT) Protein Activity and Carnitine Availability